KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to -$84.7 million.

  • CRISPR Therapeutics AG's Free Cash Flow rose 2093.12% to -$84.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$303.1 million, marking a year-over-year decrease of 5854.68%. This contributed to the annual value of -$144.7 million for FY2024, which is 4638.59% up from last year.
  • Latest data reveals that CRISPR Therapeutics AG reported Free Cash Flow of -$84.7 million as of Q3 2025, which was up 2093.12% from -$114.0 million recorded in Q2 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Free Cash Flow peaked at $780.4 million during Q2 2021, and registered a low of -$151.6 million during Q2 2022.
  • For the 5-year period, CRISPR Therapeutics AG's Free Cash Flow averaged around -$39.1 million, with its median value being -$96.8 million (2023).
  • Its Free Cash Flow has fluctuated over the past 5 years, first soared by 247311.76% in 2021, then plummeted by 15523.42% in 2024.
  • Over the past 5 years, CRISPR Therapeutics AG's Free Cash Flow (Quarter) stood at -$95.2 million in 2021, then fell by 25.52% to -$119.5 million in 2022, then increased by 19.0% to -$96.8 million in 2023, then soared by 48.06% to -$50.3 million in 2024, then plummeted by 68.46% to -$84.7 million in 2025.
  • Its Free Cash Flow stands at -$84.7 million for Q3 2025, versus -$114.0 million for Q2 2025 and -$54.2 million for Q1 2025.